Navigation Links
Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib,Combination Studies

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today the results from two Phase II non-randomized studies of seliciclib fixed dose combinations. In one study seliciclib was given in combination with gemcitabine and cisplatin and in another with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).

The primary objectives of the studies were to assess the safety and efficacy of the two combinations. In the first study, 45 patients with advanced NSCLC, who were previously untreated or treated with no more than one prior chemotherapy, were enrolled and treated with the combination of seliciclib plus gemcitabine and cisplatin. Seliciclib was administered twice daily (b.i.d.) by mouth for 4 days every week. Gemcitabine was administered once a week for two weeks followed by one week of rest. Cisplatin was administered once every three weeks. Patients were entered into 3 seliciclib cohorts dosed at 400 mg b.i.d. (n=3), 800 mg b.i.d. (n=36) and 1200 mg b.i.d. (n=6). In the second study, 7 patients with advanced NSCLC who have had one prior chemotherapy were enrolled and treated with the combination of seliciclib plus docetaxel. Seliciclib was administered at 1600 mg b.i.d. for 3 days every 3 weeks. Docetaxel was administered once every three weeks. The combination study with docetaxel was discontinued early due to slow accrual.

The best response by investigator assessment consisted of 9 patients with partial response and 21 with stable disease in patients treated with the combination of seliciclib plus gemcitabine/cisplatin and 2 with partial response and 1 with stable disease in the combination of seliciclib plus docetaxel. The major dose-limiting toxicities were nausea, vomiting, fatigue, hypokalemia and elevation in liver enzymes which were primarily attributed to seliciclib. There were no unexpected toxicities.'"/>




Page: 1 2 3

Related medicine technology :

1. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
2. Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder and ... a scientific poster describing an innovative diagnostic procedure for ... Shedding New Light on Disease (SPEC) conference in Krakow, ... Treado,s poster entitled, "Development of in vitro Diagnostics for ... be discussed during the conference poster session on Tuesday, ...
(Date:8/19/2014)... -- Tokyo-based Atonarp Inc. announced today $8 million in ... Riverwood Ventures with participation from other co-investors.  The ... technology platform, which will enable a broad range ... & gas and healthcare industries for its initial ... with Atonarp in pursuing the commercialization of its ...
(Date:8/19/2014)... – a provider-led accelerator that puts the power of ... ­– announces Sutter Health, a not-for-profit health system in ... recent addition to the AVIA Innovator Network. ... focused helping patients navigate the healthcare system and enable ... so they work as a larger team for each ...
Breaking Medicine Technology:ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... Md., Oct  27, 2011 Neuralstem, Inc. (NYSE Amex: ... in the ongoing safety trial to test its neuroregenerative small ... (MDD).  Phase Ia tested the drug in healthy volunteers for ... commence later this year, will test the safety and tolerability ...
... Oct. 27, 2011 Herborium Group, Inc., ... company, announced the following update today. ... stated: "These are truly exciting times for our Company. ... Bulletin Board exchange by maintaining Herborium, Current Information ...
Cached Medicine Technology:Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 2Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 3Herborium Group Shareholders Update 2Herborium Group Shareholders Update 3
(Date:8/20/2014)... This agreement will allow storageFOUNDRY ... networking, high availability cloud enablement, service, and elastic ... allowing OPEN-V to sell storageFOUNDRY’s expanding Nautilus line ... with OPEN-V on this distribution agreement of our ... channels at storageFOUNDRY. "Nautilus is a massively scalable, ...
(Date:8/19/2014)... well-known bamboo product manufacturer and retailer, has unveiled its new ... excited to reveal the new items, and it has decided ... every customer can get a discounted price, up to 30 ... , The company’s deckings are made of the finest quality, ... are perfect for a dining room, living room, kitchen, foyer, ...
(Date:8/19/2014)... Crosley Law Firm, PC has reached a confidential ... Star Bakery for an undisclosed amount. The two claimants, Pete ... of 2011, respectively. The injuries were caused by two different ... to the left hand of each man. , At the ... short-staffed, having lost 200 of its, 500 workers in connection ...
(Date:8/19/2014)... an outstanding company in the garment industry, has unveiled its ... to this, the company has also launched a big sale ... at low rates, up to 30 percent off. , ... bohemian outfits are available in many colours, including green, blush, ... quality clothes, reasonable prices and sincere service, the company has ...
(Date:8/19/2014)... the brain involved in multitasking and ways to train ... the IUGM Institut universitaire de griatrie de Montral and ... to better predict the effectiveness of this training. Cooking ... the Web, or driving while listening to a radio ... our daily lives. Unfortunately, it decreases with age, which ...
Breaking Medicine News(10 mins):Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Promotional Bamboo Deckings from Well-known Online Supplier BambooIndustry.com 2Health News:Crosley Law Firm Reaches Settlement for Hand Amputation Victims at Commercial Bakery 2Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Targeted brain training may help you multitask better 2
... have found out why women who have a baby when ... breast cancer. They have identified a substance produced naturally in ... pregnancy trigger the changes in the breast tissue of young ... a pill that could protect against breast cancer. ...
... franchisee for US based Medicine Shoppe International, with operations in ... list of its target for operations in the country. According ... expand its franchisee operations from the present 19 outlets to ... decided to put on hold the commencing of operations in ...
... Common childhood vaccinations, including newer ones such as those ... diabetes. The conclusion came from a look at 768 ... had juvenile diabetes. Those who had been vaccinated against ... no more likely to have developed diabetes than those ...
... hormone production may help explain why obese people who carry ... a high risk of heart disease and other health problems. ... and its complications. // ,It is no news ... heart disease and diabetes, but where these extra pounds accumulate ...
... some time that a wide range of influenza viruses circulate in ... humans. These are two subtypes of the influenza A virus known ... was reported in Hong Kong in mid-May . ,The ... six people and infect 12 others in a small but densely ...
... may not only an effective treatment for malaria, the ... be similar to the mechanism they use to ... these findings at the 50th Annual Meeting of the ... ,The compounds called disulfides, occur naturally in garlic, ...
Cached Medicine News:
... Tips are available as both regular and ... by gamma-rays for more efficient sterilization and ... specifying the date of irradiation. Sterilized Diamond ... to autoclave. SterilPack Diamond Tips are wrapped ...
This large 1000 L tip makes pipetting fragile cells, genomic DNA, and viscous samples easy. Perfect for cell culture laboratories....
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
Conducting disposable filter-tips....
Medicine Products: